• Nanosonics to conduct $20 million on-market share buy-back in FY26
• Buy-back reflects strong financial position, cash generation, and confidence in long-term growth
• Balanced capital management approach to fund strategic initiatives and deliver shareholder value

Nanosonics Limited (ASX: NAN), a global leader in infection prevention, today announces an on-market share buy-back of up to $20 million in FY26, as part of its disciplined capital management strategy. The buy-back reflects the Company's strong financial position, consistent cash generation and confidence in its long-term growth outlook. Nanosonics' CEO and President, Michael Kavanagh, stated that the company's business model is built on a solid foundation of capital revenue from trophon® device sales and growing recurring revenue from consumables and services. With no debt and a history of predictable cash flows, Nanosonics has invested decisively in its next growth horizon, developing and launching trophon3 and trophon2 Plus, and the development and FDA De Novo approval of the CORIS system. These innovations not only strengthen the company's leadership in infection prevention but also open significant new opportunities for continued growth. The Board is confident Nanosonics has sufficient cash reserves to fund its strategic initiatives, including the continued growth of the trophon business, the controlled market release and broader commercialisation of CORIS, and pursuing selective potential bolt-on acquisitions. The buy-back is a reflection of that confidence and the company's commitment to delivering long-term value to shareholders. Nanosonics remains committed to a balanced capital management approach, maintaining a strong balance sheet while investing for growth and returning capital to shareholders in a way that reflects the Company's strong fundamentals and future potential.